Seeking Alpha

Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a... More
My company:
Raygent Capital
My blog:
Raygent.com,Rayno Life Science
  • Rayno Biopharmaceutical Focus Stocks: Ones To Watch -ALXN,PCYC,REGN 0 comments
    Feb 14, 2013 7:09 PM | about stocks: IBB

    Caution is Warranted by Technicals

    Given the toppiness in the biotechnology sector and the stalling of the IBB ($146), it looks like momentum is waning and some MO stocks favored by BIG money are selling off. Nonetheless we have not made any portfolio recommendations other than raising a little cash. We will update if there is a correction with some overweighting such as Cubist (NASDAQ:CBST) and Gilead (NASDAQ:GILD) but new buys are not recommended at this time except Optimer (NASDAQ:OPTR) as we noted earlier this week, We expect a modest sell-off should NASDAQ falter and keep in mind that seasonality can be weak for stocks in late Q1.Remember the biotech sector was up 35% in 2012 and is up 6-8% in 2013 YTD. All that being said small and mid-cap stocks in our index were lively (CLDX, INCY, ISIS, NKTR) today with some big winners so speculation still abounds.

    The following focus stocks have sold off 2013 highs:

    Alexion (ALXN $87.63) Off 5% YTD.

    Amgen (AMGN $84.72) Off 1.7% YTD.

    Medivation (MDVN $53.35) MO stock hedge or short trade

    Regeneron (REGN $169.24) Off 1% YTD.

    Strong outperformers in 2013 still near highs:

    Albany Molecular (AMRI $7.87) Up 49% YTD still valued at 1X Revenues.

    Biogen Idec (BIIB $164.59) Solid technicals.

    Gilead (GILD $41.60) Solid technicals and up 13.3 % YTD. Hard to buy in on weakness.

    Immunogen (IMGN $14.50) Laggard up 13.65% YTD.

    Optimer (OPTR $11.78) Laggard up 30% YTD.

    Pharmacyclics (PCYC $80.21) Up 39% YTD but due for a correction.

    Seattle Genetics (SGEN $27.80) Up 20% YTD.

    Viropharma (VPHM $25.69)

    Here is our 2012 YTD review from December 24, 2012:

    Rayno Biopharmaceutical Focus Stocks YTD: Top Performers include AMRI,GILD, REGN | Raygent.com

    Disclosure: I am long OPTR.

    Stocks: IBB
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.